Tenaya Therapeutics, Inc. (TNYA) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
171 Oyster Point Boulevard
South San Francisco, CA 94080
United States of America (the)
Phone
650 825 6900
Sector
Healthcare
Industry
Biotechnology
Employees
70
First IPO Date
July 30, 2021
| Name | Title | Pay | Year Born |
| Faraz Ali | Chief Executive Officer, Interim Principal Financial Officer & Director | 983,964 | 1973 |
| Deepak Srivastava | Scientific Founder, Chairman of Scientific Advisory Board & Director | 90,500 | 1967 |
| Whittemore G. Tingley | Chief Medical Officer | 702,844 | 1968 |
| Michelle Corral | Vice President of Investor Relationship & Corporate Communications | 0 | N/A |
| Benoit G. Bruneau | Scientific Founder | 0 | N/A |
| Bruce R. Conklin | Scientific Founder | 0 | N/A |
| Saptarsi Haldar | Scientific Founder | 0 | N/A |
| Sheng Ding | Scientific Founder | 0 | N/A |
| Eric N. Olson | Scientific Founder & Member of Scientific Advisory Board | 0 | N/A |
| Kee-Hong Kim | Chief Technology Officer | 0 | 1966 |
| Tomohiro Higa | Senior Vice President of Finance & Interim Principal Accounting Officer | 0 | 1969 |
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration. It has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. to identify and validate novel gene targets for the potential treatment of cardiovascular disease. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.